688136 Stock Overview
Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 688136 from our risk checks.
Kexing Biopharm Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.51 |
| 52 Week High | CN¥22.82 |
| 52 Week Low | CN¥10.61 |
| Beta | 0.83 |
| 1 Month Change | -11.90% |
| 3 Month Change | -25.05% |
| 1 Year Change | -31.49% |
| 3 Year Change | -57.72% |
| 5 Year Change | n/a |
| Change since IPO | -64.62% |
Recent News & Updates
Shareholder Returns
| 688136 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -11.5% | -2.6% | -0.4% |
| 1Y | -31.5% | -26.4% | -17.6% |
Return vs Industry: 688136 underperformed the CN Biotechs industry which returned -26.9% over the past year.
Return vs Market: 688136 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 688136 volatility | |
|---|---|
| 688136 Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 688136's share price has been volatile over the past 3 months.
Volatility Over Time: 688136's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,260 | Yanqing Zhao | www.kexing.com |
Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. The company focuses on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunity, blood, digestion, and degenerative diseases. Its products include recombinant human interferon a1b, human erythropoietin, and human granulocyte stimulating factor; Clostridium butyricum combined live bacteria powder; Kehuang Capsule, a Chinese patent medicine; Entecavir, a chemical drug; and liraglutide, a human glucagon-like peptide-1, as well as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules.
Kexing Biopharm Co., Ltd. Fundamentals Summary
| 688136 fundamental statistics | |
|---|---|
| Market cap | CN¥2.89b |
| Earnings (TTM) | -CN¥189.57m |
| Revenue (TTM) | CN¥1.26b |
2.3x
P/S Ratio-15.2x
P/E RatioIs 688136 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688136 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.26b |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥1.26b |
| Other Expenses | CN¥1.45b |
| Earnings | -CN¥189.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 27, 2024
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 100.00% |
| Net Profit Margin | -15.06% |
| Debt/Equity Ratio | 64.4% |
How did 688136 perform over the long term?
See historical performance and comparison